Company / Operating Income
BIOCRYST PHARMACEUTICALS INC Operating Income History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Income
$341.0M
FY2025
5-year range
-$177.7M / $341.0M
FY2021-FY2025
Trend
+13508.9%
vs FY2024
Sector context
#22 of 204
Health Care
What the data says
Operating Income changed +13509% YoY in FY2025, a notable deviation from the 9-year average annual change of +1499%.
Based on SEC 10-K filings.
$341M in FY2025. Top quartile in the Health Care sector.
Improved from -$104M to $341M over the past 2 years.
Health Care sector context is included.
Operating Income over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Top 11% in Health CareTop 11% of 204This company $341.0M Sector average $107.8M
▼
+216.5% above sector average
Key checks
Key Insights
- BIOCRYST PHARMACEUTICALS INC's operating income has grown for 4 consecutive years.
- In FY2025, operating income increased 13508.9% year-over-year.
- Ranks #22 out of 204 companies in the Health Care sector.
- Lowest operating income in the period was in FY2021.
Company context
Key Data Points
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating IncomeValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $341.0M | +13508.9% |
| FY2024 | -$2.5M | +97.5% |
| FY2023 | -$103.7M | +30.1% |
| FY2022 | -$148.4M | +16.5% |
| FY2021 | -$177.7M | -1.7% |
| FY2020 | -$174.8M | -75.7% |
| FY2019 | -$99.5M | -5.6% |
| FY2018 | -$94.2M | -64.1% |
| FY2017 | -$57.4M | -18.1% |
| FY2016 | -$48.6M | -23.2% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026